{
    "organizations": [],
    "uuid": "b9441eff81a46aa13e4d08833fd1662805fa3871",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-five-prime-therapeutics-reports-q1/brief-five-prime-therapeutics-reports-q1-loss-per-share-0-63-idUSASC0A0MB",
    "ord_in_thread": 0,
    "title": "BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Five Prime Therapeutics Inc:\n* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.63 * Q1 EARNINGS PER SHARE VIEW $-0.55 â€” THOMSON REUTERS I/B/E/S\n* EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE LESS THAN $135 MILLION\n* ESTIMATES ENDING 2018 WITH APPROXIMATELY $250 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T04:55:00.000+03:00",
    "crawled": "2018-05-09T12:15:30.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "five",
        "prime",
        "therapeutic",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "expects",
        "net",
        "cash",
        "used",
        "operating",
        "activity",
        "less",
        "million",
        "estimate",
        "ending",
        "approximately",
        "million",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}